The relation of phacoemulsification and progression of age-related macular degeneration


  • O.U. Denisyuk Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine, Ukraine



phacoemulsification, age-related macular degeneration, occurrence, progression


Background. It is currently impossible to draw definitive conclusions whether phacoemulsification (PhE) is safe for people with age-related macular degeneration (ARMD). It is not clear if PhE causes the progression of ARMD and affects visual acuity (VA). The purpose was to analyze the possible association of PhE with ARMD progression in the early and late (up to 18 months after surgery) period. Materials and methods. The study included 86 patients (93 eyes), 37 men and 49 women aged 60 to 82 years, who were operated for PhE (implantation of soft intraocular lens on the camera Infiniti, “Alcon”, USA). ARMD was assessed based on the classification of the American Academy of Ophthalmologists (AREDS, 2001). Patients were examined 1, 3, 6, 12 and 18 months after surgery. For statistical processing of obtained data, Statistica 10 (StatSoft, Inc., USA) and MedCalc Statistical Software 18 (MedCalc Software bvba, Belgium) were used. Results. In 69.9 % of eyes with cataract, ARMD was registered: early and midstage (AREDS 2 and 3) was diagnosed in 16.1 % of cases, late stage (AREDS 4.1) — in 25.8 %, and exudative (AREDS 4.2) — in 28.0 %. VA before surgery was consistent with the stage of ARMD and was worse in AREDS 4. To evaluate the progression of ARMD, the index of progression (IP) was developed characterizing the average rate of ARMD clinical manifestations change. The progression of ARMD within 18 months (IP > 0) after the PhE was observed in 33.3 % of cases, including 12.9 % of first determined ARMD. Patients without ARMD progression were 6 years younger than those that had progression (p = 0.001). When IP = 0.100, the disorder progressed at the early stages (3 months); when IP = 0.033, in the later period (12 and 18 months). After surgery, VA was significantly increased, which depended on the initial stage of ARMD (VA was worse at the late stage and in AREDS 4) and ARMD progression (VA was worse when IP > 0, and in the cases of progression when IP = 0.033, that is, with the later ARMD progression). Conclusions. The characteristics of the stages of ARMD and VA dynamics after PhE suggest a positive impact of PhE on the ARMDS progression.


Flaxman S.R., Bourne R.R.A., Resnikoff S., Ackland P., Braithwaite T., Cicinelli M.V., Das A. et al. Vision Loss Expert Group of the Global Burden of Disease Study. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob. Health. 2017 Dec. 5(12). e1221-e1234. doi: 10.1016/S2214-109X(17)30393-5. Epub 2017 Oct 11.

Wong W.L., Su X., Li X. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta‐analysis. Lancet Glob Health. 2014. 2(2). е106-e116.

Офтальмология: клинические рекомендации. Алябьева Ж.Ю., Астахов Ю.С., Волобуева Т.М., Городничий В.В. и др. Под ред. Л.К. Мошетовой, А.П. Нестерова, Е.А. Егорова. 2009. 352 с.

Kovacević D., Misljenović T., Njirić S., Mikulicić M., Vojni­ković B. Appearance of age related maculopathy after cataract surgery. Coll. Antropol. 2008 Oct. 32 (Suppl. 2). 9-10.

Baatz H., Darawsha R., Ackermann H., Scharioth G.В., de Ortueta D., Pavlidis M., Hattenbach L.O. Phacoemulsification does not induce neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2008 Mar. 49(3). 1079-83. doi: 10.1167/iovs.07-0557.

Ehmann D.S., Ho A.C. Cataract surgery and age-related ma­cular degeneration. Curr. Opin. Ophthalmol. 2017 Jan. 28(1). 58-62. doi: 10.1097/ICU.0000000000000331.

Starr M.R., Mahr M.A., Barkmeier A.J., Iezzi R., Smith W.М., Bakri S.J. Outcomes of Cataract Surgery in Patients With Exudative Age-related Macular Degeneration and Macular Fluid. Am. J. Ophthalmol. 2018 Aug. 192. 91-97. doi: 10.1016/j.ajo.2018.05.014.

Casparis H., Lindsley K., Kuo I.С., Sikder S., Bressler N.M. Surgery for cataracts in people with age-related macular degeneration. Cochrane Database Syst. Rev. 2017 Feb 16. 2. CD006757. doi: 10.1002/14651858.CD006757.pub4.

Age-Related Eye Disease Study Research Group. A randomi­zed, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 2001 Oct. 119(10). 1417-36.

Денисюк О.Ю. Спосіб оцінювання впливу хірургічного лікування катаракти на прогресування вікової макулярної дегенерації. Архів офтальмології України. 2018. 6(2). 58-61.

Денисюк О.Ю., Риков С.А., Могілевський С.Ю. Спосіб прогнозування розвитку макулярної дегенерації після хірургічного лікування катаракти. Патент на корисну модель 130989 Україна. Заяв. 06.04.2018. Опубл. 10.01.2019. Бюл. № 1.

Umfress A.С., Brantley M.А. Jr. Eye Care Disparities and Health-Related Consequences in Elderly Patients with Age-Related Eye Disease. Semin. Ophthalmol. 2016. 31(4). 432-8. doi: 10.3109/08820538.2016.1154171.

Anastasopoulos E., Haidich A.B., Coleman A.L. et al. Risk factors for Age-related Macular Degeneration in a Greek population: The Thessaloniki Eye Study. Ophthalmic Epidemiol. 2018 Oct — Dec. 25(5-6). 457-469. doi: 10.1080/09286586.2018.1512634.

Rappoport D., Goldberg M., Bukelman A., Katz H., Goldberg L., Pollack A. Phacoemulsification in eyes with neovascular age-related macular degeneration (AMD). Harefuah. 2017 Feb. 156(2). 79-83. [Article in Hebrew]

Rim T.H., Lee C.S., Lee S.C., Kim S., Kim S.S. Epidemio­logic Survey Committee Of The Korean Ophthalmological Society. Association between Previous Cataract Surgery and Age-Related Ma­cular Degeneration. Semin. Ophthalmol. 2017. 32(4). 466-473. doi: 10.3109/08820538.2015.1119861.

Ho J.D., Xirasagar S., Kao L.Т., Lin H.C. Neovascular age-related macular degeneration is associated with cataract surgery. Acta Ophthalmol. 2018 Mar. 96(2). e213-e217. doi: 10.1111/aos.13511.